Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab plus anti-CD20 monoclonal antibody for active ANCA-associated rapidly progressive glomerulonephritis
ChiCTR2600122042Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eculizumab in crescentic glomerulonephritis (RPGN) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete response rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
eculizumab
03
Conditions
crescentic glomerulonephritis (RPGN)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on ChiCTR2600122042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122042.